ASND250117C160000
- 2.10
- 0.000.00%
Ascendis Pharma A/S Newsroom
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $153 to $220
Evercore ISI Remains a Buy on Ascendis Pharma (ASND)
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $289
Ascendis Pharma Initiated at Buy by UBS
Ascendis Pharma Analyst Ratings
UBS Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $196
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $203
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $220
Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $194
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $167 to $211
Ascendis Pharma (ASND) Gets a Buy From Stifel Nicolaus
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $153 to $207